WillItSurvive
Food tech and alternative protein · subsidiary of Novonesis A/S (formerly Novozymes A/S; Novo Holdings A/S controlling shareholder with 70.1% voting rights via A-shares) · Denmark

Chr. Hansen Holding

chr-hansen.com ↗

Danish maker of food cultures and enzymes, now part of biosolutions giant Novonesis.

Hard to displace
Assessed 25 July 2026 · Evidence as of 25 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 25 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: H1 2026 interim report, first full read on US consumer demand softness management flagged as a risk
The call

Novonesis sits on old biology, hard-won approvals, and factory-level customer ties that AI tools can speed up but not replace, leaving rival giants as the nearer competitive question.

Chr. Hansen (now part of Novonesis after merging with Novozymes in 2024) grows and sells special microbes and enzymes that food companies, farmers, and breweries use to make cheese, yogurt, animal feed, and other products. It is genuinely hard to copy because the company has spent 150 years building a library of microbe strains, has government approvals for each one, and embeds its own technical experts inside customer factories. AI can speed up finding new microbes in the lab, but it cannot create the regulatory paperwork, manufacturing plants, or customer trust that Chr. Hansen already owns. The one thing that could shift the picture is if startup biotech companies using AI actually win real customer contracts in dairy or food cultures in the next few years, rather than just making announcements; right now that is not happening, and even if it does, the threat is years away.

Why
01
AI pressure: AI-driven protein/enzyme design tools (computational strain design). AI speeds up finding new enzymes and strains in the lab, but getting them approved and into customer plants still takes years, not a prompt. Could AI do the core job? Unlikely.
02
Bigger players: DSM-Firmenich and IFF. Both rivals sell overlapping enzymes and cultures worldwide; Novonesis just paid 1.5 billion euros to take full control of a feed enzyme business it used to share with DSM-Firmenich. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of regulatory approvals, strain libraries dating to 1874, and enzymes already built into customers' factory lines make switching slow and expensive.
What would change this call
Novonesis organic growth falls below 5% in H1 or 9M 2026 interim reports. Would signal guidance miss and possible competitive or demand erosion.
Feed Enzyme Alliance integration costs still dragging net profit in FY2026 annual report (Feb 2027). Would show merger integration friction denting margins beyond forecast.
DSM-Firmenich, IFF, or Kerry announces a major merger or capacity buildout matching Novonesis scale. Would show peers closing the scale gap in strains, sites, or customer integration.
Key numbers
  • FY2025 revenue 4.16 billion euros, up 7% organic (2025-12-31)
  • Adjusted EBITDA margin 37.1% in 2025 (2025-12-31)
  • 32 manufacturing sites, 11,641 employees at year end (2025-12-31)
Named risks
  • US consumer sentiment softness could pressure H2 2026 organic growth, flagged by management but not yet evident. Severity: medium
  • Feed Enzyme Alliance integration dragged net profit by EUR 76M in Q3 2025, ongoing costs could continue through 2026. Severity: medium
  • AI-native biotech startups using computational strain design could eventually shortcut Novonesis's proprietary strain-library advantage. Severity: low
  • Tough year-over-year comparisons flagged in Agriculture, Energy and Tech segments for early 2026. Severity: low
  • Reputational spillover from Novo-affiliated Novo Nordisk's July 2026 litigation against Eli Lilly, though not Novonesis-specific. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
dsm-firmenichgaining onPaid dsm-firmenich EUR 1.5B to fully absorb Feed Enzyme Alliance, closed 2025-06-02
IFFcontestingBoth compete directly in food enzymes/cultures oligopoly per 2025-09-30 market analysis
Kerry GroupcontestingNamed peer in food enzymes/cultures market analysis dated 2025-09-30
BASFcontestingAdjacent bio-ingredients incumbent cited as peer, 2025-09-30 market report
Lallemand Animal NutritioncontestingCompetes in feed probiotics segment per 2026-02-28 market analysis
Questions people ask
Is Chr. Hansen still a separate company or did it merge with someone?
Chr. Hansen no longer exists as a standalone public company. It merged with Novozymes on January 29, 2024, forming Novonesis, with shareholder settlement completed February 2, 2024. All Chr. Hansen shares converted to Novozymes B-shares; it now trades as Novonesis (NSIS-B) on Nasdaq Copenhagen.
Is Novonesis (the merged Chr. Hansen and Novozymes) profitable?
Yes. Novonesis reported full-year 2025 net sales of EUR 4,157.6 million with 7% organic growth and a 37.1% adjusted EBITDA margin, as of December 31, 2025. 2026 guidance targets 5-7% organic growth and 37-38% EBITDA margin, per its February 25, 2026 annual report.
Could AI replace Novonesis (former Chr. Hansen) in food cultures and enzymes?
Unlikely near-term. AI tools like AlphaFold accelerate protein and strain design (Novonesis won an NSF grant for AI-driven HMO synthesis, announced September 17, 2025), but cannot replace its regulatory GRAS approvals, 150-year strain library, or 32 manufacturing sites integrated into customer production lines.
Who owns Novonesis, the company that absorbed Chr. Hansen?
Novo Holdings A/S is the controlling shareholder, holding roughly 25.5% of share capital and 70.1% of votes via A-shares as of mid-2026, according to Novozymes' Wikipedia entry dated July 18, 2026. Novonesis trades publicly on Nasdaq Copenhagen with a market cap near EUR 26 billion.
Who is Novonesis's biggest competitor after buying the Feed Enzyme Alliance?
Its closest peers in enzymes, cultures, and probiotics are DSM-Firmenich, IFF, Kerry Group, and BASF, per market-research analysis dated September 30, 2025. Novonesis strengthened its position by paying dsm-firmenich EUR 1.5 billion to fully absorb their shared Feed Enzyme Alliance, with regulatory close on June 2, 2025.
What happened to Chr. Hansen's stock ticker CHR?
The CHR ticker on Nasdaq Copenhagen was retired when Chr. Hansen shareholders exchanged shares for Novozymes B-shares at settlement on February 2, 2024. The combined company now trades under NSIS-B (previously NZYM B) as Novonesis.
Timeline
  • 2026-02-25Novonesis issues FY2026 guidance: 5-7% organic growth, 37-38% adjusted EBITDA margin
  • 2025-12-31FY2025 results: EUR 4,157.6M net sales, 7% organic growth, 37.1% EBITDA margin, 11,641 employees
  • 2025-09-309M 2025 sales reach EUR 3,161.0M with 8% organic growth
  • 2025-09-17NSF awards Novonesis funding for AI-driven cell-free HMO biomanufacturing
  • 2025-06-30H1 2025 sales EUR 2,096.1M with 9% organic growth
  • 2025-06-02Regulatory approval closes on Novonesis's EUR 1.5B takeover of Feed Enzyme Alliance from dsm-firmenich
  • 2025-05-16Novonesis launches Vertera plant-based biosolutions for high-protein vegurt market
  • 2025-02-11Novonesis agrees to pay dsm-firmenich EUR 1.5B to dissolve 25-year Feed Enzyme Alliance
  • 2024-02-02Settlement completed: Chr. Hansen shares converted to Novozymes B-shares, forming Novonesis
  • 2024-01-29Chr. Hansen and Novozymes merger legally completes, day-one headcount ~10,000
Revision history
25 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Toyo Suisan Kaisha, Ltd.IOI Corporation BerhadBunge Global
More in Food tech and alternative protein →
Sources